EHA 2021 | KdD VS Kd in R/R myeloma: TTP, TTNT and PFS2 data
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, discusses updated data from the CANDOR (NCT03158688) study and reports on time to next treatment (TTNT), time to progression (TTP), and time to second objective disease progression (PFS2) in relapsed/ refractory multiple myeloma (R/R) patients receiving either carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). At a median of 27 months of follow-up, the median progression free survival with KdD was 28.6 months, compared to 15.2 months in the Kd arm. Dr Usmani reports that treatment with KdD improved TTP, TTNT and PFS2 in comparison to Kd. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.
